SAT-094 Cardiovascular Mortality and Hyperfunctioning Pituitary Disorders: A 24-Year Retrospective Study of Gender and Racial Disparities using CDC WONDER database

Abstract Disclosure: S. Govekar: None. V. Gill: None. S. Soni: None. Introduction: Hyperfunctioning of the pituitary gland leads to excessive hormone secretion, playing a key role in homeostasis and causing systemic effects, especially on cardiovascular health. This condition disrupts metabolic regulation, blood pressure, and fluid balance, contributing to increased cardiovascular morbidity and mortality. Despite its significance, research on long-term mortality trends in hyperfunctioning pituitary disorders and coexisting cardiovascular diseases is limited. This study evaluates 24-year trends in cardiovascular mortality related to hyperfunctioning pituitary conditions, focusing on gender and racial disparities, using data from CDC WONDER (Wide-ranging Online Data for Epidemiologic Research). Methods: A retrospective analysis was conducted using CDC WONDER death certificate data (1999-2022) to examine cardiac-related mortality in individuals with pituitary hyperfunction, including acromegaly, gigantism, SIADH, and hyperprolactinemia. Deaths were identified using ICD-10 codes for cardiac conditions (I11.0, I11.9, I13.0-I13.9, I20-I51) and pituitary hyperfunction (E22.x). Variables included demographics, urban-rural status, region, and year. Crude and age-adjusted mortality rates (AAMRs) were calculated using the 2000 U.S. Census standard. Temporal trends were analyzed with Joinpoint regression (p < 0.05). Results: From 1999-2022, 11,309 deaths were attributed to pituitary hyperfunction, predominantly females (59%) and Whites (91%). Most deaths occurred in the 85+ (32%), 75-84 (28%), and 65-74 (21%) age groups. Cardiac-related mortality accounted for 11.8% (1,335 cases), mainly in females (62%) and Whites (93%), exclusively among those aged 65 and older. AAMRs for hyperpituitarism-related deaths declined significantly from 1999 to 2010 (APC = -3.43; p < 0.05), rose from 2010 to 2019 (APC = 1.11), and sharply increased from 2019 to 2022 (APC = 14.97). Cardiac-related AAMRs showed a similar rise after 2020. Conclusion: Mortality trends related to hyperpituitarism and cardiac conditions reveal increasing deaths in recent years, particularly after 2019. The presence of ACE2 receptors in the hypothalamus and pituitary may explain disruptions in the hypothalamus-pituitary axis due to COVID-19. Further research should explore age, sex, and comorbidity factors to inform prevention strategies and improve outcomes for affected individuals. Presentation: Saturday, July 12, 2025